Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.

Connell, Louise C.; Chou, Joanne F.; Boucher, Taryn Mary; Capanu, Marinela; Kemeny, Nancy E.

doi:10.1200/jco.2016.34.4_suppl.762

Cited by 6 publications

(8 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current results are found significant height in serum levels of LDH and ALP in patients with CRC when compared to controls, which is in accordance with the observations of the previous researchers (Ojo et al, 2016;Saif et al, 2005;Connell et al, 2017). Ojo and colleagues showed significantly increasing values of serum LDH and ALP enzymes in CRC compared to controls, and reported that the associations between high activities of these enzymes and risk of developing cancer could be used as tumor markers in the prognosis, diagnosis and management of cancer (Ojo et al, 2016).…”

Section: Discussionsupporting

confidence: 93%

“…Ojo and colleagues showed significantly increasing values of serum LDH and ALP enzymes in CRC compared to controls, and reported that the associations between high activities of these enzymes and risk of developing cancer could be used as tumor markers in the prognosis, diagnosis and management of cancer (Ojo et al, 2016). Consistently, Connell and workers showed that elevated serum levels of LDH at baseline significantly correlate with a poor prognosis in unresectable colorectal liver metastases (Connell et al, 2017). The increase in ALP level in GI cancer patients may probably due to destruction of tissues facilitating the leakage of enzyme and their appearance in blood circulation (Yadav, 2017).…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Serum Levels of Lactate Dehydrogenase and Alkaline Phosphatase Enzymes in Colorectal Cancer

Al-Ghurabi¹,

Yaseen²,

Hamzah³

2019

J Pure Appl Microbiol

View full text Add to dashboard Cite

Colorectal cancer (CRC) remains one of the main public health problems throughout the world. it has recently been observed that both of lactate dehydrogenase (lDh) and alkaline phosphatase (AlP) enzymes play critical role in cancer expansion. Current study was enrolled for investigating serum levels of LDH and ALP before and after surgery, as well as to assess if whether association of these enzymes with the histological grades of CRC. By using colorimetric method the activity LDH and ALP were determined in serum of 50 CRC patients before surgery, and in 30 patients after surgical compared with 30 healthy controls. The levels of LDH and ALP were increase in patients group before surgical treatment (p<0.001) than that in control group. Further, significant differences were found in the mean of serum enzymes after surgery in 30 patients, also mean serum levels of these enzymes increased in patients with advanced stages of tumor. These finding suggest that serum levels of LDH and ALP appears to be of some prognostic value in CRC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 88%

Serum Levels of Lactate Dehydrogenase and Alkaline Phosphatase Enzymes in Colorectal Cancer

Al-Ghurabi¹,

Yaseen²,

Hamzah³

2019

J Pure Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…In our study, right colon (OR, 1.550; P = 0.012) and well and moderately differentiated tumours (OR, 2.203; P = 0.001) were independent predictive factors of KRAS mutations. STMs were reported to not be associated with KRAS mutations in several studies [21,27,28]. However, negative CA199 was found to be signi cantly correlated with KRAS mutations in our study.…”

Section: Discussioncontrasting

confidence: 84%

Serum tumour markers combined with clinicopathological characteristics for predicting MMR and KRAS status in 2279 Chinese colorectal cancer patients: a retrospective analysis

Zhao

Cao

Jia

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Although serum tumour markers (STMs), clinicopathological characteristics and the status of KRAS and MMR play an important role in optimizing the treatment and improving the prognosis of colorectal cancer, their interrelationships remain largely unknown. Methods A retrospective analysis of 2279 patients who underwent KRAS or MMR status testing and STM measurements prior to treatment over the past four years was conducted. Univariate and multivariate logistic regression were performed to identify independent predictive factors of KRAS and MMR status. The area under receiver operating characteristic (ROC) curve (AUC) was used to evaluate the predictive value of individual and combined factors. Results Of the 784 patients tested for KRAS and 2279 patients tested for MMR status, KRAS mutations and dMMR were identified in 276 patients (35.20%) and 177 patients (7.77%), respectively. Logistic regression analysis demonstrated that right colon, well and moderate differentiation and negative CA19-9 were independent predictors for KRAS mutations. The ROC curve yielded an AUC of 0.609 for the combination of the three factors. Age < 65 was an independent predictive factor for dMMR, along with tumour size > 4.6 cm, right colon, poor differentiation, harvested lymph nodes ≥ 22, no lymph node metastasis, no perineural invasion, negative CEA and positive CA72-4. When the nine criteria were used together, the AUC was 0.849. Conclusion Both STMs and clinicopathological characteristics were found to be significantly associated with the status of KRAS and MMR. The combination of these two factors possessed a strong predictive power for targeted genes among CRC patients.

show abstract

“…Of the 30 patients with KRAS mutation, a mutation was found in codon 12 (22), most had only one metastatic site (90.9%). The same did not occur with patients with mutations in codon 13 (8), of which half (50.0%) had only one metastatic site (p=0.029). Figure 2 illustrates the patient's overall survival by primary site and KRAS status.…”

Section: Study Design and Ethical Standardsmentioning

confidence: 78%

Impact of Kras Mutations in Clinical Features in Colorectal Cancer

Zanatto

Santos

Oliveira

et al. 2020

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background: KRAS mutations are important events in colorectal carcinogenesis, as well as negative predictors of response to EGFR inhibitors treatment. Aim: To investigate the association of clinical-pathological features with KRAS mutations in colorectal cancer patients treated. Methods: Data from 69 patients with colorectal cancer either metastatic at diagnosis or later, were retrospectively analyzed. The direct sequencing and pyrosequencing techniques were related to KRAS exon 2. The mutation diagnosis and its type were determined. Results: KRAS mutation was identified in 43.4% of patients. The most common was c.35G>T (p.G12V), c.35G>A (p.G12D) and c.38G>A (p.G13D). No correlation was found between KRAS mutation and age (p=0.646) or gender (p=0.815). However, mutated group had higher CEA levels at admission (p=0.048) and codon 13 mutation was associated with involvement of more than one metastatic site in disease progression (p=0.029). Although there was no association between primary tumor site and mutation diagnosis (p=0.568), primary colon was associated with worse overall survival (p=0.009). Conclusion: The KRAS mutation was identified in almost half of patients. Mutated KRAS group had higher levels of CEA at admission and the mutation at codon 13 was associated with involvement of more than one metastatic site in the course of the disease. Colon disease was associated with the worst overall survival.

show abstract

Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases.

Abstract: Background-While the significance of CEA, LDH and KRAS status as individual prognostic factors for patients with metastatic colorectal cancer has been addressed, the relationship and interdependence between these prognostic factors on survival is limited.

Cited by 6 publications

References 16 publications

Serum Levels of Lactate Dehydrogenase and Alkaline Phosphatase Enzymes in Colorectal Cancer

Serum Levels of Lactate Dehydrogenase and Alkaline Phosphatase Enzymes in Colorectal Cancer

Serum tumour markers combined with clinicopathological characteristics for predicting MMR and KRAS status in 2279 Chinese colorectal cancer patients: a retrospective analysis

Impact of Kras Mutations in Clinical Features in Colorectal Cancer

Contact Info

Product

Resources

About